Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) – Pipeline Review, H2 2016’, provides in depth analysis on Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Array BioPharma Inc.

Bristol-Myers Squibb Company

Genentech, Inc.

Nimbus Therapeutics, LLC

Pfizer Inc.

Portola Pharmaceuticals, Inc.

Sareum Holdings Plc

Takeda Pharmaceutical Company Limited

Theravance Biopharma Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) Overview 7

Therapeutics Development 8

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Products under Development by Stage of Development 8

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Products under Development by Therapy Area 9

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Products under Development by Indication 10

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Products under Development by Companies 14

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Products under Development by Universities/Institutes 17

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Therapeutics Assessment 19

Assessment by Monotherapy/Combination Products 19

Assessment by Mechanism of Action 20

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Companies Involved in Therapeutics Development 25

Array BioPharma Inc. 25

Bristol-Myers Squibb Company 26

Genentech, Inc. 27

Nimbus Therapeutics, LLC 28

Pfizer Inc. 29

Portola Pharmaceuticals, Inc. 30

Sareum Holdings Plc 31

Takeda Pharmaceutical Company Limited 32

Theravance Biopharma Inc 33

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Drug Profiles 34

ARRY-111 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

cerdulatinib - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

PF-06700841 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

SAR-20347 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

SART-1 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

SART-29 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

SART-33 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Small Molecule to Inhibit TYK2 for Immunology - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecule to Inhibit TYK2 for Psoriasis and IBD - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Small Molecules to Inhibit TYK2 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Small Molecules to Inhibit Tyk2 for Oncology, Psoriasis and IBD - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

TD-1473 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Dormant Projects 51

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Discontinued Products 52

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC

2.7.10.2) - Featured News & Press Releases 53

Oct 24, 2016: Sareum Holdings: Successful Outcome from TYK2 Feasibility Study 53

Oct 04, 2016: Theravance Biopharma Announces First Subject Dosed in Phase 1b Clinical Trial of TD-1473 in Patients With Moderate to Severe Ulcerative Colitis 53

Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor 54

Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings 55

Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 56

Mar 18, 2016: Theravance Biopharma Presents Positive Results From a Preclinical Colitis Model for TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor 57

Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor 58

Dec 05, 2015: Portola Pharmaceuticals Announces Cerdulatinib Data Presentation at the 2015 American Society of Hematology Annual Meeting and Exposition 58

Nov 10, 2015: Nimbus Therapeutics Announces Progress on Key Therapeutic Programs 59

Nov 02, 2015: Theravance Biopharma Submits Investigational New Drug Application for TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor 60

Jun 17, 2015: Sareum Notified Of Funding Award From Innovate UK 60

May 29, 2015: Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib 61

May 18, 2015: Portola Pharmaceuticals Announces Upcoming Data Presentation on Dual Kinase Inhibitor Cerdulatinib at American Society of Clinical Oncology Annual Meeting 63

Nov 10, 2014: Sareum Holdings First Patent Grant for Sareum's TYK2 Kinase Inhibitor Programme 64

Nov 06, 2014: Portola Pharmaceuticals Announces Upcoming Presentations on Cerdulatinib at the American Society of Hematology 2014 Annual Meeting 64

Appendix 66

Methodology 66

Coverage 66

Secondary Research 66

Primary Research 66

Expert Panel Validation 66

Contact Us 66

Disclaimer 67

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 (Contd..1) 16

Number of Products under Investigation by Universities/Institutes, H2 2016 17

Products under Investigation by Universities/Institutes, H2 2016 18

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 22

Number of Products by Stage and Molecule Type, H2 2016 24

Pipeline by Array BioPharma Inc., H2 2016 25

Pipeline by Bristol-Myers Squibb Company, H2 2016 26

Pipeline by Genentech, Inc., H2 2016 27

Pipeline by Nimbus Therapeutics, LLC, H2 2016 28

Pipeline by Pfizer Inc., H2 2016 29

Pipeline by Portola Pharmaceuticals, Inc., H2 2016 30

Pipeline by Sareum Holdings Plc, H2 2016 31

Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 32

Pipeline by Theravance Biopharma Inc, H2 2016 33

Dormant Projects, H2 2016 51

Discontinued Products, H2 2016 52

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Routes of Administration, H2 2016 21

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Molecule Types, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 23

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports